Brief report: Reducing Lorlatinib-related Adverse Events by establishing the Optimal Exposure-Toxicity Threshold in Patients with NSCLC.
Daan A C Lanser
,
Lisanne N van Merendonk
,
G D Marijn Veerman
,
Salomé van Beusekom
,
Esther Oomen-de Hoop
,
Peter de Bruijn
,
Attila Icli
,
Marthe S Paats
,
Alwin D R Huitema
,
Ron H N van Schaik
,
Sushil Badrising
,
Anne-Marie C Dingemans
,
Ron H J Mathijssen
More about this publication
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Pages
104093
Publication date
16-07-2026
Full text links
Publisher website (DOI)
10.1016/j.jtho.2026.104093
Europe PubMed Central
42462816
Pubmed
42462816